23-Valent Pneumococcal Polysaccharide Vaccine Evaluation Service
Dive Deep into 23-Valent Pneumococcal Polysaccharide Vaccine with Precision and Clarity
23-Valent pneumococcal polysaccharide vaccine is a Streptococcus pneumoniae vaccine derived from capsular polysaccharides. Polysaccharide antigens can be used to induce specific antibodies to enhance the killing of S. pneumoniae by phagocytic immune cells. A thorough evaluation and characterization of the 23-valent pneumococcal polysaccharide vaccine is essential. CD BioGlyco has advanced technology and a reliable team to help our clients to comprehensively analyze Pharmaceutical and Biological including Pharmaceutical Analysis, Biological Evaluation, and Pharmaceutical Excipient Analysis. For vaccine evaluation, we provide high-quality Typhoid Vaccine Evaluation, Group A Meningococcal Polysaccharide Vaccine Evaluation, Haemophilus influenzae Type b Conjugate Vaccine Evaluation, and Poliomyelitis Vaccine in Dragee Candy Evaluation services.
- Single-type refined polysaccharide test
- Identification: Our researchers use double immunodiffusion to observe the precipitation lines of monotypic polysaccharides with specific sera. Moreover, we determine the content of each monotypic polysaccharide by turbidimetric inhibition immunoassay.
- Basic test: Our analysts are experienced in the analysis of total solids, protein, nucleic acid, O-acetyl, phosphorus, and total nitrogen. Our team provides professional organic solvent residue analysis and bacterial endotoxin test services.
- Determination of sugar content: Our team mainly provides accurate glucuronic acid, methylpentose, and aminocaproic acid content determination services through spectrophotometry and parallel titration.
- Molecular size determination: Our researchers determine the partition coefficients of bacterial capsular polysaccharides by advanced high-performance liquid chromatography(HPLC) with a differential refractive index detector.
- Vaccine test
- Determination of each type of polysaccharide content: Our researchers obtain standard curves by reacting polysaccharide standard solutions with specific serum. The product to be tested is diluted and reacted with polysaccharide-specific serum, and the content of each type of polysaccharide is measured by a turbidimeter.
- Physical chemistry determination: We provide precise volume, pH, osmolality, and phenol content test services.
- Biological determination: We provide high-quality sterility tests, abnormal toxicity tests, pyrogen tests, and bacterial endotoxin test services.
Publication Data
Technology: Quantitative multiplex immunoassay (Luminex technology)
Journal: Vaccines
Published: 2023
IF: 4.961
Results: The researchers quantified pneumococcal IgG concentrations for five serotypes common to both vaccines and four serotypes specific to the 23-valent polysaccharide vaccine before and 8 weeks after vaccination. Analysis of the last measured serum IgG antibody levels, lymphocyte counts, hemoglobin levels, and platelet levels showed statistically significant (p < 0.001) increases in all serotype-specific antibody concentrations after vaccination compared to previous antibody levels.
Fig.1 Mapping of serotype-specific antibody concentrations before and after vaccination. (Haggenburg, et al., 2023)
Applications
- Comprehensive evaluation of 23-valent pneumococcal polysaccharide vaccines may help control the progression of chronic obstructive pulmonary disease (COPD).
- Comprehensive evaluation of the 23-valent pneumococcal polysaccharide vaccine contributes to the development and improvement of the 13-valent, 7-valent pneumococcal vaccine.
Advantages of Us
- Relying on state-of-the-art analytical systems and specialized analysts, we offer a full range of polysaccharide vaccine evaluation services from physicochemical analysis to bioactivity testing.
- For sugar content measurements, our operators conduct parallel tests to ensure the accuracy and validity of the data.
- Our experienced analytical team develops polysaccharide vaccine evaluation solutions for our clients based on their requirements, and our goal is to complete each project efficiently and with high quality.
Under the operation of the industry-experienced staff, CD BioGlyco provides a 23-valent pneumococcal polysaccharide vaccine evaluation service to obtain systematic and accurate experimental data. Our company places extra emphasis on the client experience. Please feel free to contact us with any inquiries.
Reference
- Haggenburg, S.; et al. Immunogenicity of the 13-valent pneumococcal conjugated vaccine followed by the 23-valent polysaccharide vaccine in chronic lymphocytic leukemia. Vaccines. 2023, 11(7): 1201.
